Antisense Therapeutics trial of ATL1101 in prostate cancer shows promise
June 20th, 2009 Posted in hormone therapyAntisense Therapeutics Ltd. has reported further positive results from its collaborative preclinical research studies on the therapeutic potential of ATL1101 in prostate cancer. In experimental models, ATL1101 treatment significantly enhanced the tumor-suppressive effect of the cancer drug Paclitaxel. Paclitaxel is one of a class of drugs known as taxanes.
Along with androgen (a male hormone) blockade, taxane chemotherapy is an important treatment option in the most dangerous form of the disease, castration-resistant prostate cancer (CRPC).